Teal Health, a women’s health and cancer screening company, has raised $22 million in Series A funding, the company announced on Tuesday.
The San Francisco-based company’s flagship product is the Teal Wand, an FDA-authorized at-home device for HPV cervical cancer screening. Teal Health’s telehealth platform also provides access to providers, who can go over the results of the screening. If follow-up care is needed, the company helps connect patients with that care.
The Series A round was led by .406 Ventures, with support from Emerson Collective (managed by Yosemite), Forerunner, Serena Ventures and Japan-based MPower Partners. In total, Teal Health has raised $45 million.
Why Pharma Companies Should Look To Social Media For Better Patient Insight
Healthcare decision-makers, especially at pharmaceutical companies, must prioritize patient input. Data collected from social media listening is a significant step in the right direction.
“Patients are demanding more convenient ways to access healthcare, and Teal has proven that convenience doesn’t have to come at the expense of accuracy,” said Kathryn Taylor Reddy, partner at .406 Ventures, in a statement.
The financing will help Teal Health grow its network of payer, health system, employer, provider and brand partnerships. The company is also expanding its direct-purchase options for individuals and organizations.
A Teal Health cervical cancer screening kit costs $99 with insurance and $249 for self-pay. Currently, the company accepts insurance from Aetna, Anthem, Cigna, BlueCross BlueShield and UnitedHealthcare. In January 2027, federal guidelines will also require most health plans to cover self-collection for cervical cancer screening.
“With broad insurance coverage for self-collection beginning in January 2027, Teal is focused on making at-home screening available to more women through the channels where they already receive care and make healthcare decisions,” said Kara Egan, CEO and founder of Teal Health, in an email.
From Blind Spots to Better Outcomes: How SNF Data Transparency Strengthens LTSS
What if health plans could identify member decline before an avoidable hospitalization occurs? Real-time clinical visibility into long-stay SNF members uncovers risk earlier and drives better outcomes.
Teal Health’s funding comes as about one in three U.S. women have never been screened for cervical cancer, and finding a traditional in-person screening can be difficult due to a lack of appointment availability. It’s predicted that in 2026, about 4,200 women will die from cervical cancer, according to the American Cancer Society.
“Teal Health’s next phase is focused on scaling at-home cervical cancer screening from an early-adopter option into a routine part of preventive care,” Egan said. “The company plans to expand its national reach, grow partnerships across the healthcare ecosystem and continue building the clinical evidence around self-collection. Teal will also continue improving the end-to-end experience, from at-home sample collection and telehealth through results and follow-up care.”
Photo: Andriy Onufriyenko, Getty Images